Armata Pharmaceuticals (ARMP) Price to Earnings (2013 - 2026)

Armata Pharmaceuticals has disclosed Price to Earnings across 14 years of filings, most recently posting 14.2 for Q2 2026.

• In Q2 2026, Price to Earnings fell 120.02% year-over-year to 14.2; the TTM figure through Jun 2026 stood at 3.88 (down 176.0% YoY), while the FY2025 annual figure was 4.3, down 241.49% from the prior year.
• Price to Earnings came in at 14.2 for Q2 2026 at Armata Pharmaceuticals, up from 26.16 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 4.3 in Q2 2023 to a low of 26.16 in Q1 2026.
• Average Price to Earnings over 5 years is 10.38, with a median of 9.23 recorded in 2023.
• Year-over-year, Price to Earnings surged 82.21% in 2022 and plunged 483.82% in 2026.
• Over 5 years, Price to Earnings stood at 4.35 in 2022, then plunged by 145.72% to 10.68 in 2023, then soared by 54.63% to 4.84 in 2024, then tumbled by 153.16% to 12.26 in 2025, then fell by 15.83% to 14.2 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 14.2 in Q2 2026, 26.16 in Q1 2026, and 12.26 in Q4 2025.